Ertapenem for Initial Empirical Treatment of Third Generation Cephalosporin Resistant Enterobacteriaceae Bacteremia

A Study to Assess the Safety, Tolerability and Efficacy of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-048)

NCT00379951 ·Status: COMPLETED ·Phase: PHASE3

Impact of the Choice of 3rd Generation Cephalosporins on the Emergence of Resistance in the Microbiota Intestinal.

NCT02659033 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate the Safety and Effectiveness of Ertapenem Versus Ceftriaxone/Metronidazole in the Treatment of Intra-abdominal Infections in Adults (0826-802)

NCT00481702 ·Status: COMPLETED ·Phase: PHASE3

Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae

NCT02420366 ·Status: COMPLETED

A Study to Evaluate Ertapenem Versus It's Comparator in the Treatment of Complicated Intra-abdominal Infections in Adults (0826-050)(COMPLETED)

NCT00157898 ·Status: COMPLETED ·Phase: PHASE4

T.E.A. Study Three Days Ertapenem Versus Three Days Ampicillin- Sulbactam

NCT00630513 ·Status: COMPLETED ·Phase: PHASE4

Ertapenem Sodium vs. Piperacillin/Tazobactam in the Treatment of Complicated Intra-Abdominal Infections (0826-037)

NCT00389987 ·Status: COMPLETED ·Phase: PHASE3

Carbapenem-resistant Enterobacteriaceae: Prevalence, Risk Factors and Impact of the Use of the Phenotypic Algorithm for the Detection of Carbapenemases

NCT02127450 ·Status: COMPLETED

Prevalence of Enterobacteria With Decreased Susceptibility to Carbapenems in Eastern Inter- Region

NCT02803710 ·Status: UNKNOWN

Identification of Gut Microbiome Biomarkers Associated to Acquisition of Enterobacteriae Highly Resistant to Third Generation Cephalosporines Following Ceftriaxone Treatment.

NCT03569917 ·Status: TERMINATED ·Phase: NA

Community-associated Highly-Resistant Enterobacterales

NCT03924934 ·Status: COMPLETED

Clinical Significance and Optimal Treatment of Community-onset Urinary Tract Infections Caused by Extended-spectrum β-lactamase and/or AmpC β-lactamase Producing Enterobacteriaceae

NCT01138566 ·Status: UNKNOWN

Safety of Ertapenem in Beta-lactam Allergic Patients.

NCT01159379 ·Status: UNKNOWN ·Phase: PHASE4

Hospital Microbial Ecology Follow the Introduction of Ertapenem and Other Newly Introduced Antibiotic Over Time

NCT01611025 ·Status: UNKNOWN

Impact on the Intestinal Microbiota of Treatment With Ceftriaxone in Women's Acute Community Pyelonephritis

NCT03179384 ·Status: COMPLETED ·Phase: PHASE4

Phenotypic Profile and Molecular Mechanism of Resistance in Carbapenemase-producing Enterobacterales and Pseudomonas Aeruginosa Isolates From Brazilian Hospitals: Implications for the Introduction of IMIPENEM-RELEBACTAM

NCT05285046 ·Status: UNKNOWN

Precise Treatment of Ceftazidime-Avibactam in Patients With CRO Infections Under the Guidance of TDM and PPK Model

NCT06210542 ·Status: NOT_YET_RECRUITING

Emergence of Resistance in Intestinal Microflora During Carbapenem Treatments

NCT01703299 ·Status: COMPLETED

Efficacy and Safety of Ertapenem Sodium (MK-0826) Following Colorectal Surgery in Chinese Adults (MK-0826-056)

NCT01254344 ·Status: COMPLETED ·Phase: PHASE3

GSK2251052 in the Treatment of Complicated Intra-abdominal Infections

NCT01381562 ·Status: TERMINATED ·Phase: PHASE2

Impact of Ceftazidime / Avibactam Treatment vs Better Available Therapy on Mortality of Patients With Infections Caused by Carbapenem-resistant Enterobacteria

NCT04167228 ·Status: COMPLETED

FMT to Eradicate Intestinal Colonization by Carbapenem-resistant Enterobacteriaceae

NCT05791396 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Carbapenem Antibiotic Therapy for VIM Carbapenemase-Producing Enterobacteriaceae Infections

NCT06185153 ·Status: RECRUITING

Sitafloxacin and Ertapenem Treatment for Acute Urinary Tract Infection Caused by E. Coli or K. Pneumoniae in Post-kidney Transplantation Patients

NCT02729116 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

WGS-guided Tracking and Infection Control Measures of CRKP

NCT04413305 ·Status: UNKNOWN ·Phase: NA